Sera Prognostics, Inc. (SERA) Investor Relations Documents

Sera Prognostics, Inc. (SERA) investor relations documents from the company's IR site: 1 presentation, 7 press releases; latest deck 2026-05-20. Read in-app with summaries. First-party data.

2026 Corporate Presentation: Sera Prognostics is a women's health diagnostics company whose flagship PreTRM test uses proteomics to predict spontaneous preterm birth risk.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-09Press releasePRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDE
2026-06-30Press releaseSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
2026-06-24Press releaseSERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
2026-06-23Press releaseSERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
2026-06-01Press releaseSERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
2026-05-20Presentation2026 Corporate Presentation
2026-05-06DocumentSERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
2026-03-18DocumentSERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
2026-02-17Press releaseSERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
2026-01-07Press releaseLandmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
2025-11-13DocumentSERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

SERA overview · SERA earnings · SERA financials · SERA KPIs · SERA documents · SERA ownership · SERA peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.